Contact us

877-469-1TRM
424-208-8866

Bioequivalence Study of Doxorubicin Hydrochloride Liposome Injection in Patients With Ovarian Cancer

A Randomized, Open Label, Crossover of Bioequivalence and Safety of Doxorubicin Hydrochloride Liposome Injection Formulations in Patients With Advanced Carcinoma of the Ovary

Please contact TRM directly for questions or patient referrals.

Patient Population Investigational Product(s) Phase Status
Advanced Ovarian Cancer Doxorubicin HCL Liposome I Closed